Prospera Private Wealth LLC Acquires 11,777 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Prospera Private Wealth LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1,587.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,519 shares of the medical equipment provider's stock after acquiring an additional 11,777 shares during the period. Intuitive Surgical accounts for approximately 1.1% of Prospera Private Wealth LLC's holdings, making the stock its 23rd largest position. Prospera Private Wealth LLC's holdings in Intuitive Surgical were worth $6,150,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mirador Capital Partners LP raised its holdings in shares of Intuitive Surgical by 1.4% in the 3rd quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider's stock valued at $1,732,000 after purchasing an additional 50 shares during the period. Advisors Asset Management Inc. boosted its stake in shares of Intuitive Surgical by 18.1% during the 1st quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider's stock worth $2,945,000 after acquiring an additional 1,129 shares during the period. Consolidated Planning Corp increased its holdings in shares of Intuitive Surgical by 17.4% during the 3rd quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider's stock worth $3,979,000 after acquiring an additional 1,198 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in Intuitive Surgical by 617.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider's stock valued at $39,622,000 after acquiring an additional 76,649 shares during the period. Finally, ABLE Financial Group LLC bought a new position in Intuitive Surgical during the third quarter worth $604,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on ISRG. BTIG Research set a $535.00 target price on shares of Intuitive Surgical in a research note on Friday, October 18th. Redburn Atlantic upgraded Intuitive Surgical from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Stifel Nicolaus upped their target price on Intuitive Surgical from $475.00 to $525.00 and gave the company a "buy" rating in a research report on Friday, October 18th. Truist Financial lifted their price target on Intuitive Surgical from $520.00 to $570.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Finally, Oppenheimer reaffirmed a "market perform" rating on shares of Intuitive Surgical in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $524.61.

Intuitive Surgical Price Performance

ISRG stock traded up $0.29 during midday trading on Wednesday, reaching $539.11. 372,298 shares of the stock were exchanged, compared to its average volume of 1,454,173. Intuitive Surgical, Inc. has a 52 week low of $304.50 and a 52 week high of $544.38. The company has a fifty day moving average price of $501.42 and a 200 day moving average price of $460.69. The stock has a market capitalization of $192.02 billion, a PE ratio of 86.63, a P/E/G ratio of 5.19 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares in the company, valued at approximately $1,461,006.84. This trade represents a 93.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Jamie Samath sold 22,903 shares of the business's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the transaction, the insider now directly owns 8,757 shares in the company, valued at approximately $4,597,425. This trade represents a 72.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 91,178 shares of company stock worth $45,897,071. Company insiders own 0.80% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.